Biomarkers in heart failure: A clinical review

Heart Failure Reviews

Volumn 15, Issue 4, 2010, Pages 251-273

  Paul Rocchiccioli, J ^a   McMurray, John J V ^a   Dominiczak, Anna F ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

Biomarkers; Diagnosis; Heart failure; Neurohormones; Remodelling; Risk stratification

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); ADRENOMEDULLIN; ANGIOTENSIN RECEPTOR ANTAGONIST; APELIN; ATRIAL NATRIURETIC FACTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CANDESARTAN; CARVEDILOL; CELL ADHESION MOLECULE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENDOTHELIN; FATTY ACID BINDING PROTEIN; GALECTIN 3; MILRINONE; MYOSIN LIGHT CHAIN; NATRIURETIC FACTOR; NEUROHORMONE; NORADRENALIN; PLACEBO; SODIUM; SPIRONOLACTONE; TROPONIN; TUMOR MARKER; UNINDEXED DRUG; UROCORTIN; VALSARTAN;

ANEMIA; BLOOD DISEASE; CARDIAC RESYNCHRONIZATION THERAPY; CELL DAMAGE; CELL DEATH; CLINICAL TRIAL; DEFIBRILLATOR; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG MECHANISM; DRUG TARGETING; EMERGENCY CARE; EXTRACELLULAR MATRIX; GLOMERULUS FILTRATION RATE; HEART FAILURE; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE CELL; HEART TRANSPLANTATION; HEART VENTRICLE REMODELING; HORMONAL REGULATION; HUMAN; INFLAMMATION; KIDNEY DYSFUNCTION; OUTPATIENT CARE; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRIMARY MEDICAL CARE; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; RISK ASSESSMENT; SCREENING TEST; SYSTOLIC DYSFUNCTION;

BIOLOGICAL MARKERS; CARDIOTONIC AGENTS; EMERGENCY SERVICE, HOSPITAL; HEART FAILURE; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; INFLAMMATION; NATRIURETIC AGENTS; NEUROTRANSMITTER AGENTS; PROGNOSIS; RISK ASSESSMENT; SYNDROME; SYSTOLE; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 77956884408     PISSN: 13824147     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10741-008-9123-9     Document Type: Review

References (185)

1. Stewart S, MacIntyre K, Capewell S, McMurray JJ (2003) Heart failure and the aging population: an increasing burden in the 21st century? Heart 89(1):49-53
2. Swedberg K, Cleland J, Dargie H, Drexler H, Follath F, Komajda M, Tavazzi L, Smiseth OA, Gavazzi A, Haverich A, Hoes A, Jaarsma T, Korewicki J, Levy S, Linde C, Lopez-Sendon JL, Nieminen MS, Pierard L, WJ Remme (2005) Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): the task force for the diagnosis and treatment of chronic heart failure of the European Society of Cardiology. Eur Heart J 26(11):1115-1140
3. Thomas JT, Kelly RF, Thomas SJ, Stamos TD, Albasha K, Parrillo JE, Calvin JE (2002) Utility of history, physical examination, electrocardiogram, and chest radiograph for differentiating normal from decreased systolic function in patients with heart failure. Am J Med 112(6):437-445
4. Fung ET, Wright GL Jr, Dalmasso EA (2000) Proteomic strategies for biomarker identification: progress and challenges. Curr Opin Mol Ther 2(6):643-650
5. Mann DL, Bristow MR (2005) Mechanisms and models in heart failure: the biomechanical model and beyond. Circulation 111(21):2837-2849
6. de Bold AJ, Borenstein HB, Veress AT, Sonnenberg H (1981) A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. Life Sci 28(1):89-94
7. Mukoyama M, Nakao K, Hosoda K, Suga S, Saito Y, Ogawa Y, Shirakami G, Jougasaki M, Obata K, Yasue H et al (1991) Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 87(4):1402-1412
8. Vanderheyden M, Bartunek J, Goethals M (2004) Brain and other natriuretic peptides: molecular aspects. Eur J Heart Fail 6(3):261-268
9. Vasan RS (2004) Expanding indications for natriuretic peptides: importance of better new (research) protocols. Am Heart J 148(5):743-746
10. Omland T, Aakvaag A, Bonarjee VV, Caidahl K, Lie RT, Nilsen DW, Sundsfjord JA, Dickstein K (1996) Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction comparison with plasma atrial natriuretic peptide and n-terminal proatrial natriuretic peptide. Circulation 93(11):1963-1969
11. Tsutamoto T, Wada A, Maeda K, Hisanaga T, Mabuchi N, Hayashi M, Ohnishi M, Sawaki M, Fujii M, Horie H, Sugimoto Y, Kinoshita M (1999) Plasma brain natriuretic peptide level as a biochemical marker of morbidity and mortality in patients with asymptomatic or minimally symptomatic left ventricular dysfunction comparison with plasma angiotensin II and endothelin-1. Eur Heart J 20(24):1799-1807
12. Petrie MC, Hillier C, Johnston F, McMurray JJ (2001) Effect of neutral endopeptidase inhibition on the actions of adrenomedullin and endothelin-1 in resistance arteries from patients with chronic heart failure. Hypertension 38(3):412-416
13. Lainchbury JG, Campbell E, Frampton CM, Yandle TG, Nicholls MG, Richards AM (2003) Brain natriuretic peptide and Nterminal brain natriuretic peptide in the diagnosis of heart failure in patients with acute shortness of breath. J Am Coll Cardiol 42(4):728-735
14. Redfield MM, Rodeheffer RJ, Jacobsen SJ, Mahoney DW, Bailey KR, Burnett JC Jr (2002) Plasma brain natriuretic peptide concentration: impact of age and sex. J Am Coll Cardiol 40:976-982
15. Bayes-Genis A, Lloyd-Jones DM, van Kimmenade RR, Lainchbury JG, Richards AM, Ordonez-Llanos J, Santalo M, Pinto YM, Januzzi JL Jr (2007) Effect of body mass index on diagnostic and prognostic usefulness of amino-terminal pro-brain natriuretic peptide in patients with acute dyspnea. Arch Intern Med 167(4):400-407
16. McCullough PA, Sandberg KR (2003) B-type natriuretic peptide and renal disease. Heart Fail Rev 8(4):355-358
17. Anwaruddin S, Lloyd-Jones DM, Baggish A, Chen A, Krauser D, Tung R, Chae C, Januzzi JL Jr (2006) Renal function, congestive heart failure, and amino-terminal pro-brain natriuretic peptide measurement: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study. J Am Coll Cardiol 47(1):91-97
18. Schou M, Gustafsson F, Nielsen PH, Madsen LH, Kjaer A, Hildebrandt PR (2007) Unexplained week-to-week variation in BNP and NT-proBNP is low in chronic heart failure patients during steady state. Eur J Heart Fail 9(1):68-74
19. Wu AH (2006) Serial testing of B-type natriuretic peptide and NTpro-BNP for monitoring therapy of heart failure: the role of biologic variation in the interpretation of results. Am Heart J 152(5):828-834
20. Schou M, Gustafsson F, Kjaer A, Hildebrandt PR (2007) Longterm clinical variation of NT-proBNP in stable chronic heart failure patients. Eur Heart J 28(2):177-182
21. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW, Antman EM, Smith SC Jr, Adams CD, Anderson JL, Faxon DP, Fuster V, Halperin JL, Hiratzka LF, Jacobs AK, Nishimura R, Ornato JP, Page RL, Riegel B (2005) ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: Endorsed by the Heart Rhythm Society. Circulation 112(12):e154-e235
22. Wang CS, FitzGerald JM, Schulzer M, Mak E, Ayas NT (2005) Does this dyspneic patient in the emergency department have congestive heart failure? JAMA 294(15):1944-1956
23. Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, Omland T, Storrow AB, Abraham WT, Wu AH, Clopton P, Steg PG, Westheim A, Knudsen CW, Perez A, Kazanegra R, Herrmann HC, McCullough PA (2002) Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 347(3):161-167
24. Januzzi JL Jr, Camargo CA, Anwaruddin S, Baggish AL, Chen AA, Krauser DG, Tung R, Cameron R, Nagurney JT, Chae CU, Lloyd-Jones DM, Brown DF, Foran-Melanson S, Sluss PM, Lee-Lewandrowski E, Lewandrowski KB (2005) The N-terminal Pro-BNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study. Am J Cardiol 95(8):948-954
25. Baggish AL, Siebert U, Lainchbury JG, Cameron R, Anwaruddin S, Chen A, Krauser DG, Tung R, Brown DF, Richards AM, Januzzi JL Jr (2006) A validated clinical and biochemical score for the diagnosis of acute heart failure: the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) acute heart failure score. Am Heart J 151(1):48-54
26. Mueller T, Gegenhuber A, Poelz W, Haltmayer M (2005) Diagnostic accuracy of B type natriuretic peptide and amino terminal proBNP in the emergency diagnosis of heart failure. Heart 91(5):606-612
27. British Thoracic Society Standards of Care Committee Pulmonary Embolism Guideline Development Group (2003) British Thoracic Society guidelines for the management of suspected acute pulmonary embolism. Thorax 58(6):470-483
28. Zaphiriou A, Robb S, Murray-Thomas T, Mendez G, Fox K, McDonagh T, Hardman SM, Dargie HJ, Cowie MR (2005) The diagnostic accuracy of plasma BNP and NTproBNP in patients referred from primary care with suspected heart failure: results of the UK natriuretic peptide study. Eur J Heart Fail 7(4):537-541
29. Cowie MR, Struthers AD, Wood DA, Coats AJ, Thompson SG, Poole-Wilson PA, Sutton GC (1997) Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet 350(9088):1349-1353
30. Wright SP, Doughty RN, Pearl A, Gamble GD, Whalley GA, Walsh HJ, Gordon G, Bagg W, Oxenham H, Yandle T, Richards M, Sharpe N (2003) Plasma amino-terminal pro-brain natriuretic peptide and accuracy of heart-failure diagnosis in primary care: a randomized, controlled trial. J Am Coll Cardiol 42(10):1793-1800
31. Craig J, Bradbury I, Cummins E, Downe S, Foster L, Stout A (2005) The use of B-type naturetic peptides (BNP and NTproBNP) in the investigation of patients with suspected heart failure. 2005 ed. Glasgow: NHS Quality Improvement Scotland; 2005 (Health Technology Assessment Report 6)
32. Scottish Intercollegiate Guidelines Network. Management of chronic heart failure. A national clinical guideline. Edinburgh: SIGN; 2007. Report No.: (SIGN Guideline no 95). Available from url: http://www.sign.ac.uk
33. Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Omland T, Wolf PA, Vasan RS (2004) Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 350(7):655-663
34. Vasan RS, Benjamin EJ, Larson MG, Leip EP, Wang TJ, Wilson PW, Levy D (2002) Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham Heart Study. JAMA 288(10):1252-1259
35. Costello-Boerrigter LC, Boerrigter G, Redfield MM, Rodeheffer RJ, Urban LH, Mahoney DW, Jacobsen SJ, Heublein DM, Burnett JC Jr (2006) Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: determinants and detection of left ventricular dysfunction. J Am Coll Cardiol 47(2):345-353
36. McDonagh TA, Holmer S, Raymond I, Luchner A, Hildebrant P, Dargie HJ (2004) NT-proBNP and the diagnosis of heart failure: a pooled analysis of three European epidemiological studies. Eur J Heart Fail 6(3):269-273
37. Jourdain P, Funck F, Bellorini M, Guillard N, Loiret J, Thebault B, Desnos M, Duboc D (2003) Bedside B-type natriuretic peptide and functional capacity in chronic heart failure. Eur J Heart Fail 5(2):155-160
38. Berger R, Stanek B, Frey B, Sturm B, Huelsmann M, Bergler-Klein J, Pacher R (2001) B-type natriuretic peptides (BNP and PRO-BNP) predict longterm survival in patients with advanced heart failure treated with atenolol. J Heart Lung Transplant 20(2):251
39. Cheng V, Kazanagra R, Garcia A, Lenert L, Krishnaswamy P, Gardetto N, Clopton P, Maisel A (2001) A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. J Am Coll Cardiol 37(2):386-391
40. Fisher C, Berry C, Blue L, Morton JJ, McMurray J (2003) Nterminal pro B type natriuretic peptide, but not the new putative cardiac hormone relaxin, predicts prognosis in patients with chronic heart failure. Heart 89(8):879-881
41. Harrison A, Morrison LK, Krishnaswamy P, Kazanegra R, Clopton P, Dao Q, Hlavin P, Maisel AS (2002) B-type natriuretic peptide predicts future cardiac events in patients presenting to the emergency department with dyspnea. Ann Emerg Med 39(2):131-138
42. Doust JA, Pietrzak E, Dobson A, Glasziou P (2005) How well does b-type natriuretic peptide predict death and cardiac events in patients with heart failure: systematic review. BMJ 330(7492):625
43. Anand IS, Fisher LD, Chiang YT, Latini R, Masson S, Maggioni AP, Glazer RD, Tognoni G, Cohn JN (2003) Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 107(9):1278-1283
44. Hartmann F, Packer M, Coats AJ, Fowler MB, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Anker SD, Amann-Zalan I, Hoersch S, Katus HA (2004) Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial. Circulation 110(13):1780-1786
45. Maisel A, Hollander JE, Guss D, McCullough P, Nowak R, Green G, Saltzberg M, Ellison SR, Bhalla MA, Bhalla V, Clopton P, Jesse R (2004) Primary results of the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT). A multicenter study of B-type natriuretic peptide levels, emergency department decision making, and outcomes in patients presenting with shortness of breath. J Am Coll Cardiol 44(6):1328-1333
46. Logeart D, Thabut G, Jourdain P, Chavelas C, Beyne P, Beauvais F, Bouvier E, Solal AC (2004) Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure. J Am Coll Cardiol 43(4):635-641
47. Dahle TG, Miller LW (2005) Using changes in B-type naturetic peptide levels between hospital admission and discharge to predict mortality of patients with heart failure. J Am Coll Cardiol 45:138A
48. Verdiani V, Nozzoli C, Bacci F, Cecchin A, Rutili MS, Paladini S, Olivotto I (2005) Pre-discharge B-type natriuretic peptide predicts early recurrence of decompensated heart failure in patients admitted to a general medical unit. Eur J Heart Fail 7(4):566-571
49. Gardner RS, Chong V, Morton I, McDonagh TA (2005) Nterminal brain natriuretic peptide is a more powerful predictor of mortality than endothelin-1, adrenomedullin and tumour necrosis factor-alpha in patients referred for consideration of cardiac transplantation. Eur J Heart Fail 7(2):253-260
50. Gardner RS, Ozalp F, Murday AJ, Robb SD, McDonagh TA (2003) N-terminal pro-brain natriuretic peptide. A new gold standard in predicting mortality in patients with advanced heart failure. Eur Heart J 24(19):1735-1743
51. Gardner RS, Chong KS, Morton JJ, McDonagh TA (2007) A change in N-terminal pro-brain natriuretic peptide is predictive of outcome in patients with advanced heart failure. Eur J Heart Fail 9(3):266-271
52. Komajda M, Follath F, Swedberg K, Cleland J, Aguilar JC, Cohen-Solal A, Dietz R, Gavazzi A, van Gilst WH, Hobbs R, Korewicki J, Madeira HC, Moiseyev VS, Preda I, Widimsky J, Freemantle N, Eastaugh J, Mason J (2003) The EuroHeart Failure Survey Programme - a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Eur Heart J 24(5):464-474 (Pubitemid 36286188)
53. Tsutamoto T, Wada A, Maeda K, Mabuchi N, Hayashi M, Tsutsui T, Ohnishi M, Sawaki M, Fujii M, Matsumoto T, Matsui T, Kinoshita M (2001) Effect of spironolactone on plasma brain natriuretic peptide and left ventricular remodeling in patients with congestive heart failure. J Am Coll Cardiol 37(5):1228-1233
54. Richards AM, Doughty R, Nicholls MG, MacMahon S, Ikram H, Sharpe N, Espiner EA, Frampton C, Yandle TG (1999) Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. Circulation 99(6):786-792
55. Yoshimura M, Mizuno Y, Nakayama M, Sakamoto T, Sugiyama S, Kawano H, Soejima H, Hirai N, Saito Y, Nakao K, Yasue H, Ogawa H (2002) B-type natriuretic peptide as a marker of the effects of enalapril in patients with heart failure. Am J Med 112(9):716-720
56. Fung JW, Yu CM, Yip G, Chan S, Yandle TG, Richards AM, Nicholls MG, Sanderson JE (2003) Effect of beta blockade (carvedilol or metoprolol) on activation of the renin-angiotensin-aldosterone system and natriuretic peptides in chronic heart failure. Am J Cardiol 92(4):406-410
57. Murdoch DR, McDonagh TA, Byrne J, Blue L, Farmer R, Morton JJ, Dargie HJ (1999) Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: randomized comparison of the hemodynamic and neuroendocrine effects of tailored versus empirical therapy. Am Heart J 138(6 Pt 1):1126-1132
58. Richards AM, Doughty R, Nicholls MG, MacMahon S, Sharpe N, Murphy J, Espiner EA, Frampton C, Yandle TG (2001) Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. J Am Coll Cardiol 37(7):1781-1787
59. Berger R, Huelsman M, Strecker K, Bojic A, Moser P, Stanek B, Pacher R (2002) B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation 105(20):2392-2397
60. Klingenberg R, Zugck C, Becker R, Schellberg D, Heinze G, Kell R, Remppis A, Schoels W, Katus HA, Dengler TJ (2006) Raised B-type natriuretic peptide predicts implantable cardioverter-defibrillator therapy in patients with ischaemic cardiomyopathy. Heart 92(9):1323-1324
61. Sinha AM, Filzmaier K, Breithardt OA, Kunz D, Graf J, Markus KU, Hanrath P, Stellbrink C (2003) Usefulness of brain natriuretic peptide release as a surrogate marker of the efficacy of long-term cardiac resynchronization therapy in patients with heart failure. Am J Cardiol 91(6):755-758
62. Molhoek SG, Bax JJ, van Erven L, Bootsma M, Steendijk P, Lentjes E, Boersma E, van der Laarse A, van der Wall EE, Schalij MJ (2004) Atrial and brain natriuretic peptides as markers of response to resynchronisation therapy. Heart 90(1):97-98
63. Yu CM, Fung JW, Zhang Q, Chan CK, Chan I, Chan YS, Kong SL, Sanderson JE, Lam CW (2005) Improvement of serum NTproBNP predicts improvement in cardiac function and favorable prognosis after cardiac resynchronization therapy for heart failure. J Card Fail 11(5 Suppl):S42-S46
64. Fruhwald FM, Fahrleitner-Pammer A, Berger R, Leyva F, Freemantle N, Erdmann E, Gras D, Kappenberger L, Tavazzi L, Daubert JC, Cleland JG (2007) Early and sustained effects of cardiac resynchronization therapy on N-terminal pro-B-type natriuretic peptide in patients with moderate to severe heart failure and cardiac dyssynchrony. Eur Heart J 28(13):1592-1597
65. Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM (2000) Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 355(9210):1126-1130
66. Jourdain P, Jondeau G, Funck F, Gueffet P, LeHelloco A, Donal E, Aupetit JF, Aumont MC, Galinier M, Eicher JC, Cohen-Solal A, JuilliereY(2007) Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. J Am Coll Cardiol 49(16):1733-1739
67. Lainchbury JG, Troughton RW, Frampton CM, Yandle TG, Hamid A, Nicholls MG, Richards AM (2006) NTproBNP-guided drug treatment for chronic heart failure: design and methods in the "BATTLESCARRED" trial. Eur J Heart Fail 8(5):532-538
68. Brunner-La Rocca HP, Buser PT, Schindler R, Bernheim A, Rickenbacher P, Pfisterer M (2006) Management of elderly patients with congestive heart failure - design of the Trial of Intensified versus standard Medical Therapy in Elderly patients with Congestive Heart Failure (TIME-CHF). Am Heart J 151(5):949-955
69. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, Simon AB, Rector T (1984) Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 311(13):819-823
70. Benedict CR, Shelton B, Johnstone DE, Francis G, Greenberg B, Konstam M, Probstfield JL, Yusuf S (1996) Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction. SOLVD investigators. Circulation 94(4):690-697
71. Givertz MM, Braunwald E (2004) Neurohormones in heart failure: predicting outcomes, optimizing care. Eur Heart J 25(4):281-282
72. Dzau VJ, Packer M, Lilly LS, Swartz SL, Hollenberg NK, Williams GH (1984) Prostaglandins in severe congestive heart failure. Relation to activation of the renin-angiotensin system and hyponatremia. N Engl J Med 310(6):347-352
73. Lilly LS, Dzau VJ, Williams GH, Rydstedt L, Hollenberg NK (1984) Hyponatremia in congestive heart failure: implications for neurohumoral activation and responses to orthostasis. J Clin Endocrinol Metab 59(5):924-930
74. Lee WH, Packer M (1986) Prognostic importance of serum sodium concentration and its modification by convertingenzyme inhibition in patients with severe chronic heart failure. Circulation 73(2):257-267
75. Levine TB, Franciosa JA, Vrobel T, Cohn JN (1982) Hyponatraemia as a marker for high renin heart failure. Br Heart J 47(2):161-166
76. Pulignano G, Del Sindaco D, Tavazzi L, Lucci D, Gorini M, Leggio F, Porcu M, Scherillo M, Opasich C, Di Lenarda A, Senni M, Maggioni AP (2002) Clinical features and outcomes of elderly outpatients with heart failure followed up in hospital cardiology units: data from a large nationwide cardiology database (IN-CHF registry). Am Heart J 143(1):45-55
77. Klein L, O'Connor CM, Leimberger JD, Gattis-Stough W, Pina IL, Felker GM, Adams KF Jr, Califf RM, Gheorghiade M (2005) Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study. Circulation 111(19):2454-2460
78. Rohde LE, Goldraich L, Polanczyk CA, Borges AP, Biolo A, Rabelo E, Beck-Da-Silva L, Clausell N (2006) A simple clinically based predictive rule for heart failure in-hospital mortality. J Card Fail 12(8):587-593
79. Wei CM, Lerman A, Rodeheffer RJ, McGregor CG, Brandt RR, Wright S, Heublein DM, Kao PC, Edwards WD, Burnett JC Jr (1994) Endothelin in human congestive heart failure. Circulation 89(4):1580-1586
80. Krum H, Goldsmith R, Wilshire-Clement M, Miller M, Packer M (1995) Role of endothelin in the exercise intolerance of chronic heart failure. Am J Cardiol 75(17):1282-1283
81. Pousset F, Isnard R, Lechat P, Kalotka H, Carayon A, Maistre G, Escolano S, Thomas D, Komajda M (1997) Prognostic value of plasma endothelin-1 in patients with chronic heart failure. Eur Heart J 18(2):254-258
82. Masson S, Latini R, Anand IS, Barlera S, Judd D, Salio M, Perticone F, Perini G, Tognoni G, Cohn JN (2006) The prognostic value of big endothelin-1 in more than 2, 300 patients with heart failure enrolled in the Valsartan Heart Failure Trial (Val-HeFT). J Card Fail 12(5):375-380
83. Selvais PL, Robert A, Ahn S, van Linden F, Ketelslegers JM, Pouleur H, Rousseau MF (2000) Direct comparison between endothelin-1, N-terminal proatrial natriuretic factor, and brain natriuretic peptide as prognostic markers of survival in congestive heart failure. J Card Fail 6(3):201-207
84. Bunton DC, Petrie MC, Hillier C, Johnston F, McMurray JJ (2004) The clinical relevance of adrenomedullin: a promising profile? Pharmacol Ther 103(3):179-201
85. Pousset F, Masson F, Chavirovskaia O, Isnard R, Carayon A, Golmard JL, Lechat P, Thomas D, Komajda M (2000) Plasma adrenomedullin, a new independent predictor of prognosis in patients with chronic heart failure. Eur Heart J 21(12):1009-1014
86. Richards AM, Nicholls MG, Yandle TG, Frampton C, Espiner EA, Turner JG, Buttimore RC, Lainchbury JG, Elliott JM, Ikram H, Crozier IG, Smyth DW (1998) Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation 97(19):1921-1929
87. Nishikimi T, Miyata A, Horio T, Yoshihara F, Nagaya N, Takishita S, Yutani C, Matsuo H, Matsuoka H, Kangawa K (2000) Urocortin, a member of the corticotropin-releasing factor family, in normal and diseased heart. Am J Physiol Heart Circ Physiol 279(6):H3031-H3039
88. Ng LL, Loke IW, O'Brien RJ, Squire IB, Davies JE (2004) Plasma urocortin in human systolic heart failure. Clin Sci (Lond) 106(4):383-388
89. Goetze JP, Rehfeld JF, Carlsen J, Videbaek R, Andersen CB, Boesgaard S, Friis-Hansen L (2006) Apelin: a new plasma marker of cardiopulmonary disease. Regul Pept 133(1-3):134-138
90. Chong KS, Gardner RS, Morton JJ, Ashley EA, McDonagh TA (2006) Plasma concentrations of the novel peptide apelin are decreased in patients with chronic heart failure. Eur J Heart Fail 8(4):355-360
91. Chen MM, Ashley EA, Deng DX, Tsalenko A, Deng A, Tabibiazar R, Ben Dor A, Fenster B, Yang E, King JY, Fowler M, Robbins R, Johnson FL, Bruhn L, McDonagh T, Dargie H, Yakhini Z, Tsao PS, Quertermous T (2003) Novel role for the potent endogenous inotrope apelin in human cardiac dysfunction. Circulation 108(12):1432-1439
92. Mann DL (1999) Mechanisms and models in heart failure: a combinatorial approach. Circulation 100(9):999-1008
93. Anwaruddin S, Askari AT, Topol EJ (2007) Redefining risk in acute coronary syndromes using molecular medicine. J Am Coll Cardiol 49(3):279-289
94. Aviles RJ, Askari AT, Lindahl B, Wallentin L, Jia G, Ohman EM, Mahaffey KW, Newby LK, Califf RM, Simoons ML, Topol EJ, Berger P, Lauer MS (2002) Troponin T levels in patients with acute coronary syndromes, with or without renal dysfunction. N Engl J Med 346(26):2047-2052
95. Sato Y, Yamada T, Taniguchi R, Nagai K, Makiyama T, OkadaH, Kataoka K, Ito H, Matsumori A, Sasayama S, Takatsu Y (2001) Persistently increased serum concentrations of cardiac troponin t in patients with idiopathic dilated cardiomyopathy are predictive of adverse outcomes. Circulation 103(3):369-374
96. Horwich TB, Patel J, MacLellan WR, Fonarow GC (2003) Cardiac troponin I is associated with impaired hemodynamics, progressive left ventricular dysfunction, and increased mortality rates in advanced heart failure. Circulation 108(7):833-838
97. Del Carlo CH, Pereira-Barretto AC, Cassaro-Strunz C, Latorre MdoR, Ramires JA (2004) Serial measure of cardiac troponin T levels for prediction of clinical events in decompensated heart failure. J Card Fail 10(1):43-48
98. Hudson MP, O'Connor CM, Gattis WA, Tasissa G, Hasselblad V, Holleman CM, Gaulden LH, Sedor F, Ohman EM (2004) Implications of elevated cardiac troponin T in ambulatory patients with heart failure: a prospective analysis. Am Heart J 147(3):546-552
99. Latini R, Masson S, Anand IS, Missov E, Carlson M, Vago T, Angelici L, Barlera S, Parrinello G, Maggioni AP, Tognoni G, Cohn JN (2007) Prognostic value of very low plasma concentrations of troponin T in patients with stable chronic heart failure. Circulation 116(11):1242-1249
100. Ishii J, Cui W, Kitagawa F, Kuno T, Nakamura Y, Naruse H, Mori Y, Ishikawa T, Nagamura Y, Kondo T, Oshima H, Nomura M, Ezaki K, Hishida H (2003) Prognostic value of combination of cardiac troponin T and B-type natriuretic peptide after initiation of treatment in patients with chronic heart failure. Clin Chem 49(12):2020-2026
101. Perna ER, Macin SM, Cimbaro Canella JP, Szyszko A, Franciosi V, Vargas, Morales W, Bayol AP, Kriskovich JO, Medina F, Gonzalez AB, Brizuela M (2006) Importance of early combined N-terminal pro-brain natriuretic peptide and cardiac troponin T measurements for long-term risk stratification of patients with decompensated heart failure. J Heart Lung Transplant 25(10):1230-1240
102. Sakhuja R, Green S, Oestreicher EM, Sluss PM, Lee-Lewandrowski E, Lewandrowski KB, Januzzi JL Jr (2007) Aminoterminal pro-brain natriuretic peptide, brain natriuretic peptide, and troponin T for prediction of mortality in acute heart failure. Clin Chem 53(3):412-420 (Pubitemid 46447937)
103. Hansen MS, Stanton EB, Gawad Y, Packer M, Pitt B, Swedberg K, Rouleau JL (2002) Relation of circulating cardiac myosin light chain 1 isoform in stable severe congestive heart failure to survival and treatment with flosequinan. Am J Cardiol 90(9):969-973
104. Sugiura T, Takase H, Toriyama T, Goto T, Ueda R, DohiY(2005)Circulating levels of myocardial proteins predict future deterioration of congestive heart failure. J Card Fail 11(7):504-509
105. Schaap FG, van der Vusse GJ, Glatz JF (1998) Fatty acidbinding proteins in the heart. Mol Cell Biochem 180(1-2):43-51
106. Setsuta K, Seino Y, Ogawa T, Arao M, Miyatake Y, Takano T (2002) Use of cytosolic and myofibril markers in the detection of ongoing myocardial damage in patients with chronic heart failure. Am J Med 113(9):717-722
107. Niizeki T, Takeishi Y, Arimoto T, Takahashi T, Okuyama H, Takabatake N, Nozaki N, Hirono O, Tsunoda Y, Shishido T, Takahashi H, Koyama Y, Fukao A, Kubota I (2005) Combination of heart-type fatty acid binding protein and brain natriuretic peptide can reliably risk stratify patients hospitalized for chronic heart failure. Circ J 69(8):922-927
108. Niizeki T, Takeishi Y, Arimoto T, Takabatake N, Nozaki N, Hirono O, Watanabe T, Nitobe J, Harada M, Suzuki S, Koyama Y, Kitahara T, Sasaki T, Kubota I (2007) Heart-type fatty acidbinding protein is more sensitive than troponin T to detect the ongoing myocardial damage in chronic heart failure patients. J Card Fail 13(2):120-127
109. Deschamps AM, Spinale FG (2006) Pathways of matrix metalloproteinase induction in heart failure: bioactive molecules and transcriptional regulation. Cardiovasc Res 69(3):666-676
110. Sundstrom J, Evans JC, Benjamin EJ, Levy D, Larson MG, Sawyer DB, Siwik DA, Colucci WS, Sutherland P, Wilson PW, Vasan RS (2004) Relations of plasma matrix metalloproteinase-9 to clinical cardiovascular risk factors and echocardiographic left ventricular measures: the Framingham Heart Study. Circulation 109(23):2850-2856 (Pubitemid 38786446)
111. Rossi A, Cicoira M, Golia G, Zanolla L, Franceschini L, Marino P, Graziani M, Zardini P (2004) Amino-terminal propeptide of type III procollagen is associated with restrictive mitral filling pattern in patients with dilated cardiomyopathy: a possible link between diastolic dysfunction and prognosis. Heart 90(6):650-654
112. Mizon-Gerard F, de Groote P, Lamblin N, Hermant X, Dallongeville J, Amouyel P, Bauters C, Helbecque N (2004) Prognostic impact of matrix metalloproteinase gene polymorphisms in patients with heart failure according to the aetiology of left ventricular systolic dysfunction. Eur Heart J 25(8):688-693
113. Sundstrom J, Evans JC, Benjamin EJ, Levy D, Larson MG, Sawyer DB, Siwik DA, Colucci WS, Wilson PW, Vasan RS (2004) Relations of plasma total TIMP-1 levels to cardiovascular risk factors and echocardiographic measures: the Framingham Heart Study. Eur Heart J 25(17):1509-1516
114. Kelly D, Cockerill G, Ng LL, Thompson M, Khan S, Samani NJ, Squire IB (2007) Plasma matrix metalloproteinase-9 and left ventricular remodelling after acute myocardial infarction in man: a prospective cohort study. Eur Heart J 28(6):711-718
115. Anker SD, von Haehling S (2004) Inflammatory mediators in chronic heart failure: an overview. Heart 90(4):464-470 (Pubitemid 38406929)
116. Vasan RS, Sullivan LM, Roubenoff R, Dinarello CA, Harris T, Benjamin EJ, Sawyer DB, Levy D, Wilson PW, D'Agostino RB (2003) Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation 107(11):1486-1491 (Pubitemid 36378485)
117. Levine B, Kalman J, Mayer L, Fillit HM, Packer M (1990) Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med 323(4):236-241
118. Cicoira M, Bolger AP, Doehner W, Rauchhaus M, Davos C, Sharma R, Al Nasser FO, Coats AJ, Anker SD (2001) High tumour necrosis factor-alpha levels are associated with exercise intolerance and neurohormonal activation in chronic heart failure patients. Cytokine 15(2):80-86
119. Deswal A, Petersen NJ, Feldman AM, Young JB, White BG, Mann DL (2001) Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone Trial (VEST). Circulation 103(16):2055-2059 (Pubitemid 32373007)
120. Gwechenberger M, Hulsmann M, Berger R, Graf S, Springer C,Stanek B, Pacher R (2004) Interleukin-6 and B-type natriuretic peptide are independent predictors for worsening of heart failure in patients with progressive congestive heart failure. J Heart Lung Transplant 23(7):839-844
121. Kell R, Haunstetter A, Dengler TJ, Zugck C, Kubler W, Haass M (2002) Do cytokines enable risk stratification to be improved in NYHA functional class III patients? Comparison with other potential predictors of prognosis. Eur Heart J 23(1):70-78
122. Maeda K, Tsutamoto T, Wada A, Mabuchi N, Hayashi M, Tsutsui T, Ohnishi M, Sawaki M, Fujii M, Matsumoto T, Kinoshita M (2000) High levels of plasma brain natriuretic peptide and interleukin-6 after optimized treatment for heart failure are independent risk factors for morbidity and mortality in patients with congestive heart failure. JAmColl Cardiol 36(5):1587-1593
123. Tsutamoto T, Hisanaga T, Fukai D, Wada A, Maeda Y, Maeda K, Kinoshita M
124. Yin WH, Chen JW, Young MS, Lin SJ (2007) Increased endothelial monocyte adhesiveness is related to clinical outcomes in chronic heart failure. Int J Cardiol 121(3):276-283
125. Rivera M, Talens-Visconti R, Sirera R, Bertomeu V, Salvador A, Cortes R, Garcia de Burgos F, Climent V, Paya R, Martinez-Dolz L, Sancho-Tello MJ, Gonzalez-Molina A (2004) Soluble TNF-alpha and interleukin-6 receptors in the urine of heart failure patients their clinical value and relationship with plasma levels. Eur J Heart Fail 6(7):877-882
126. Weinberg EO, Shimpo M, Hurwitz S, Tominaga S, Rouleau JL, Lee RT (2003) Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation 107(5):721-726
127. Stumpf C, Lehner C, Eskafi S, Raaz D, Yilmaz A, Ropers S, Schmeisser A, Ludwig J, Daniel WG, Garlichs CD (2003) Enhanced levels of CD154 (CD40 ligand) on platelets in patients with chronic heart failure. Eur J Heart Fail 5(5):629-637
128. Ingelsson E, Arnlov J, Sundstrom J, Lind L (2005) Inflammation, as measured by the erythrocyte sedimentation rate, is an independent predictor for the development of heart failure. J Am Coll Cardiol 45(11):1802-1806
129. Suleiman M, Khatib R, Agmon Y, Mahamid R, Boulos M, Kapeliovich M, Levy Y, Beyar R, Markiewicz W, Hammerman H, Aronson D (2006) Early inflammation and risk of long-term development of heart failure and mortality in survivors of acute myocardial infarction predictive role of C-reactive protein. J Am Coll Cardiol 47(5):962-968
130. Yin WH, Chen JW, Jen HL, Chiang MC, Huang WP, Feng AN,Young MS, Lin SJ (2004) Independent prognostic value of elevated high-sensitivity C-reactive protein in chronic heart failure. Am Heart J 147(5):931-938
131. Anand IS, Latini R, Florea VG, Kuskowski MA, Rector T, Masson S, Signorini S, Mocarelli P, Hester A, Glazer R, Cohn JN (2005) C-reactive protein in heart failure: prognostic value and the effect of valsartan. Circulation 112(10):1428-1434
132. Ruilope LM, Van Veldhuisen DJ, Ritz E, Luscher TF (2001) Renal function: the Cinderella of cardiovascular risk profile. J Am Coll Cardiol 38:1782-1787
133. Hillege HL, Nitsch D, Pfeffer MA, Swedberg K, McMurray JJ, Yusuf S, Granger CB, Michelson EL, Ostergren J, Cornel JH, de Zeeuw D, Pocock S, van Veldhuisen DJ (2006) Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. Circulation 113(5):671-678
134. Smilde TF, Hillege HL, Voors AA, Dunselman PH, van Veldhuisen DJ (2004) Prognostic importance of renal function in patients with early heart failure and mild left ventricular dysfunction. Am J Cardiol 94:240-243
135. National Kidney Foundation (2002) K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39:S1-266
136. Kazama JJ, Kutsuwada K, Ataka K, Maruyama H, Gejyo F (2002) Serum cystatin C reliably detects renal dysfunction in patients with various renal diseases. Nephron 91(1):13-20
137. Koenig W, Twardella D, Brenner H, Rothenbacher D (2005) Plasma concentrations of cystatin C in patients with coronary heart disease and risk for secondary cardiovascular events: more than simply a marker of glomerular filtration rate. Clin Chem 51(2):321-327 (Pubitemid 40175801)
138. Arimoto T, Takeishi Y, Niizeki T, Takabatake N, Okuyama H, Fukui A, Tachibana H, Nozaki N, Hirono O, Tsunoda Y, Miyashita T, Shishido T, Takahashi H, Koyama Y, Kubota I (2005) Cystatin C, a novel measure of renal function, is an independent predictor of cardiac events in patients with heart failure. J Card Fail 11(8):595-601
139. Ix JH, Shlipak MG, Chertow GM, Whooley MA (2007) Association of cystatin C with mortality, cardiovascular events, and incident heart failure among persons with coronary heart disease: data from the Heart and Soul Study. Circulation 115(2):173-179
140. Lassus J, Harjola VP, Sund R, Siirila-Waris K, Melin J, Peuhkurinen K, Pulkki K, Nieminen MS (2007) Prognostic value of cystatin C in acute heart failure in relation to other markers of renal function and NT-proBNP. Eur Heart J 28(15):1841-1847
141. Katz SD (2004) Mechanisms and treatment of anemia in chronic heart failure. Congest Heart Fail 10:243-247
142. Horwich TB, Fonarow GC, Hamilton MA, MacLellan WR, Borenstein J (2002) Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. J Am Coll Cardiol 39(11):1780-1786
143. Ezekowitz JA, McAlister FA, Armstrong PW (2003) Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12065 patients with new-onset heart failure. Circulation 107(2):223-225
144. Kosiborod M, Curtis JP, Wang Y, Smith GL, Masoudi FA, Foody JM, Havranek EP, Krumholz HM (2005) Anemia and outcomes in patients with heart failure: a study from the National Heart Care Project. Arch Intern Med 165(19):2237-2244 (Pubitemid 41549919)
145. Maggioni AP, Opasich C, Anand I, Barlera S, Carbonieri E, Gonzini L, Tavazzi L, Latini R, Cohn J (2005) Anemia in patients with heart failure: prevalence and prognostic role in a controlled trial and in clinical practice. J Card Fail 11(2):91-98
146. Mozaffarian D, Nye R, Levy WC (2003) Anemia predicts mortality in severe heart failure: the prospective randomized amlodipine survival evaluation (PRAISE). J Am Coll Cardiol 41(11):1933-1939
147. Berry C, Norrie J, Hogg K, Brett M, Stevenson K, McMurray JJ (2006) The prevalence, nature, and importance of hematologic abnormalities in heart failure. Am Heart J 151(6):1313-1321
148. Van Veldhuisen DJ, McMurray JJ (2007) Are erythropoietin stimulating proteins safe and efficacious in heart failure? Why we need an adequately powered randomised outcome trial. Eur J Heart Fail 9(2):110-112
149. Androne AS, Katz SD, Lund L, LaManca J, Hudaihed A, Hryniewicz K, Mancini DM (2003) Hemodilution is common in patients with advanced heart failure. Circulation 107(2):226-229
150. Al Ahmad A, Rand WM, Manjunath G, Konstam MA, Salem DN, Levey AS, Sarnak MJ (2001) Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J Am Coll Cardiol 38(4):955-962
151. Sharma R, Francis DP, Pitt B, Poole-Wilson PA, Coats AJ, Anker SD (2004) Haemoglobin predicts survival in patients with chronic heart failure: a substudy of the ELITE II trial. Eur Heart J 25(12):1021-1028
152. Anand I, McMurray JJ, Whitmore J, Warren M, Pham A, McCamish MA, Burton PB (2004) Anemia and its relationship to clinical outcome in heart failure. Circulation 110(2):149-154
153. Anand IS, Kuskowski MA, Rector TS, Florea VG, Glazer RD, Hester A, Chiang YT, Aknay N, Maggioni AP, Opasich C, Latini R, Cohn JN (2005) Anemia and change in hemoglobin over time related to mortality and morbidity in patients with chronic heart failure: results from Val-HeFT. Circulation 112(8):1121-1127
154. Komajda M, Anker SD, Charlesworth A, Okonko D, Metra M, Di Lenarda A, Remme W, Moullet C, Swedberg K, Cleland JG, Poole-Wilson PA (2006) The impact of new onset anaemia on morbidity and mortality in chronic heart failure: results from COMET. Eur Heart J 27(12):1440-1446
155. O'Meara E, Clayton T, McEntegart MB, McMurray JJ, Lang CC, Roger SD, Young JB, Solomon SD, Granger CB, Ostergren J, Olofsson B, Michelson EL, Pocock S, Yusuf S, Swedberg K, Pfeffer MA (2006) Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) program. Circulation 113(7):986-994
156. Lauer MS, Evans JC, Levy D (1992) Prognostic implications of subclinical left ventricular dilatation and systolic dysfunction in men free of overt cardiovascular disease (the Framingham Heart Study). Am J Cardiol 70(13):1180-1184
157. Gardner RS, Chong KS, Morton JJ, McDonagh TA (2005) Nterminal brain natriuretic peptide, but not anemia, is a powerful predictor of mortality in advanced heart failure. J Card Fail 11(5 Suppl):S47-S53
158. Wu AH, Omland T, Wold Knudsen C, McCord J, Nowak RM, Hollander JE, Duc P, Storrow AB, Abraham WT, Clopton P, Maisel AS, McCullough PA (2005) Relationship of B-type natriuretic peptide and anemia in patients with and without heart failure: a substudy from the breathing not properly (BNP) multinational study. Am J Hematol 80(3):174-180 (Pubitemid 41579538)
159. Baggish AL, van Kimmenade R, Bayes-Genis A, Davis M, Lainchbury JG, Frampton C, Pinto Y, Richards MA, Januzzi JL (2007) Hemoglobin and N-terminal pro-brain natriuretic peptide: independent and synergistic predictors of mortality in patients with acute heart failure results from the International Collaborative of NT-proBNP (ICON) Study. Clin Chim Acta 381(2):145-150
160. Ozkalemkas F, Ali R, Ozkocaman V, Ozcelik T, Ozan U, Ozturk H, Kurt E, Evrensel T, Yerci O, Tunali A (2005) The bone marrow aspirate and biopsy in the diagnosis of unsuspected nonhematologic malignancy: a clinical study of 19 cases. BMC Cancer 5:144
161. Spell DW, Jones DV Jr, Harper WF, David Bessman J (2004) The value of a complete blood count in predicting cancer of the colon. Cancer Detect Prev 28(1):37-42
162. Pierce CN, Larson DF (2005) Inflammatory cytokine inhibition of erythropoiesis in patients implanted with a mechanical circulatory assist device. Perfusion 20(2):83-90
163. Hamilton CA, Miller WH, Al Benna S, Brosnan MJ, Drummond RD, McBride MW, Dominiczak AF (2004) Strategies to reduce oxidative stress in cardiovascular disease. Clin Sci (Lond) 106(3):219-234
164. Berry C, Hamilton CA, Brosnan MJ, Magill FG, Berg GA, McMurray JJ, Dominiczak AF (2000) Investigation into the sources of superoxide in human blood vessels: angiotensin II increases superoxide production in human internal mammary arteries. Circulation 101(18):2206-2212
165. Hokamaki J, Kawano H, Yoshimura M, Soejima H, Miyamoto S, Kajiwara I, Kojima S, Sakamoto T, Sugiyama S, Hirai N, Shimomura H, Nagayoshi Y, Tsujita K, Shioji I, Sasaki S, Ogawa H (2004) Urinary biopyrrins levels are elevated in relation to severity of heart failure. J Am Coll Cardiol 43(10):1880-1885
166. McMurray J, Chopra M, Abdullah I, Smith WE, Dargie HJ (1993) Evidence of oxidative stress in chronic heart failure in humans. Eur Heart J 14(11):1493-1498
167. Keith M, Geranmayegan A, Sole MJ, Kurian R, Robinson A, Omran AS, Jeejeebhoy KN (1998) Increased oxidative stress in patients with congestive heart failure. J Am Coll Cardiol 31(6):1352-1356
168. Nonaka-Sarukawa M, Yamamoto K, Aoki H, Takano H, Katsuki T, Ikeda U, Shimada K (2003) Increased urinary 15-F2t-isoprostane concentrations in patients with non-ischaemic congestive heart failure: a marker of oxidative stress. Heart 89(8):871-874
169. Wykretowicz A, Furmaniuk J, Smielecki J, Deskur-Smielecka E, Szczepanik A, Banaszak A, Wysocki H (2004) The oxygen stress index and levels of circulating interleukin-10 and interleukin-6 in patients with chronic heart failure. Int J Cardiol 94(2-3):283-287
170. White M, Ducharme A, Ibrahim R, Whittom L, Lavoie J, Guertin MC, Racine N, He Y, Yao G, Rouleau JL, Schiffrin EL, Touyz RM (2006) Increased systemic inflammation and oxidative stress in patients with worsening congestive heart failure: improvement after short-term inotropic support. Clin Sci (Lond) 110(4):483-489
171. White M, Lepage S, Lavoie J, De Denus S, Leblanc MH, Gossard D, Whittom L, Racine N, Ducharme A, Dabouz F, Rouleau JL, Touyz R (2007) Effects of combined candesartan and ACE inhibitors on BNP, markers of inflammation and oxidative stress, and glucose regulation in patients with symptomatic heart failure. J Card Fail 13(2):86-94
172. Doehner W, Anker SD (2005) Uric acid in chronic heart failure. Semin Nephrol 25(1):61-66
173. Anker SD, Doehner W, Rauchhaus M, Sharma R, Francis D, Knosalla C, Davos CH, Cicoira M, Shamim W, Kemp M, Segal R, Osterziel KJ, Leyva F, Hetzer R, Ponikowski P, Coats AJ (2003) Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. Circulation 107(15):1991-1997
174. Batin P, Wickens M, McEntegart D, Fullwood L, Cowley AJ (1995) The importance of abnormalities of liver function tests in predicting mortality in chronic heart failure. Eur Heart J 16(11):1613-1618
175. Cicoira M, Zanolla L, Rossi A, Golia G, Franceschini L, Brighetti G, Zeni P, Zardini P (2002) Elevated serum uric acid levels are associated with diastolic dysfunction in patients with dilated cardiomyopathy. Am Heart J 143(6):1107-1111
176. Pascual-Figal DA, Hurtado-Martinez JA, Redondo B, Antolinos MJ, Ruiperez JA, Valdes M (2007) Hyperuricaemia and longterm outcome after hospital discharge in acute heart failure patients. Eur J Heart Fail 9(5):518-524
177. Jortani SA, Valdes R Jr (2001) Mammalian cardenolides as biomarkers in congestive heart failure. Cardiovasc Toxicol 1(2):165-170
178. Balzan S, Neglia D, Ghione S, D'Urso G, Baldacchino MC, Montali U, L'Abbate A (2001) Increased circulating levels of ouabain-like factor in patients with asymptomatic left ventricular dysfunction. Eur J Heart Fail 3(2):165-171
179. Sjovall K, Nilsson B, Einhorn N (2002) The significance of serum CA 125 elevation in malignant and nonmalignant diseases. Gynecol Oncol 85(1):175-178
180. Kouris NT, Zacharos ID, Kontogianni DD, Goranitou GS, Sifaki MD, Grassos HE, Kalkandi EM, Babalis DK (2005) The significance of CA125 levels in patients with chronic congestive heart failure. Correlation with clinical and echocardiographic parameters. Eur J Heart Fail 7(2):199-203
181. D'Aloia A, Faggiano P, Aurigemma G, Bontempi L, Ruggeri G, Metra M, Nodari S, Dei Cas L (2003) Serum levels of carbohydrate antigen 125 in patients with chronic heart failure: relation to clinical severity, hemodynamic and Doppler echocardiographic abnormalities, and short-term prognosis. J Am Coll Cardiol 41(10):1805-1811
182. Kosar F, Aksoy Y, Ozguntekin G, Ozerol I, Varol E (2006) Relationship between cytokines and tumour markers in patients with chronic heart failure. Eur J Heart Fail 8(3):270-274
183. Sharma UC, Pokharel S, van Brakel TJ, van Berlo JH, Cleutjens JP, Schroen B, Andre S, Crijns HJ, Gabius HJ, Maessen J, Pinto YM (2004) Galectin-3 marks activated macrophages in failureprone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 110(19):3121-3128
184. van Kimmenade RR, Januzzi JL Jr,Ellinor PT, Sharma UC, Bakker JA, Low AF, Martinez A, Crijns HJ, MacRae CA, Menheere PP, Pinto YM (2006) Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. J Am Coll Cardiol 48(6):1217-1224
185. Granger CB, McMurray JJ (2006) Using measures of disease progression to determine therapeutic effect: a sirens' song. J Am Coll Cardiol 48(3):434-437